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Note from the Editors: Instructions for reviewers of study protocols
Since launching in 2011, BMJ Open has published study protocols for planned or ongoing research 
studies. If data collection is complete, we will not consider the manuscript.
Publishing study protocols enables researchers and funding bodies to stay up to date in their fields 
by providing exposure to research activity that may not otherwise be widely publicised. This can help 
prevent unnecessary duplication of work and will hopefully enable collaboration. Publishing 
protocols in full also makes available more information than is currently required by trial registries 
and increases transparency, making it easier for others (editors, reviewers and readers) to see and 
understand any deviations from the protocol that occur during the conduct of the study.
The scientific integrity and the credibility of the study data depend substantially on the study design 
and methodology, which is why the study protocol requires a thorough peer-review. 
BMJ Open will consider for publication protocols for any study design, including observational 
studies and systematic reviews.
Some things to keep in mind when reviewing the study protocol: 
 Protocol papers should report planned or ongoing studies. The dates of the study should be 
included in the manuscript. 
 Unfortunately we are unable to customize the reviewer report form for study protocols. As 
such, some of the items (i.e., those pertaining to results) on the form should be scored as 
Not Applicable (N/A).
 While some baseline data can be presented, there should be no results or conclusions 
present in the study protocol. 
 For studies that are ongoing, it is generally the case that very few changes can be made to 
the methodology. As such, requests for revisions are generally clarifications for the rationale 
or details relating to the methods. If there is a major flaw in the study that would prevent a 
sound interpretation of the data, we would expect the study protocol to be rejected. 
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Abstract
Aims
There has been a paradigm shift proposing that comorbidities are a major contributor towards the 
heart failure with preserved ejection fraction (HFpEF) syndrome. Furthermore, HFpEF patients have 
abnormal macro and microvascular function, which may significantly contribute towards altered 
ventriculo-vascular coupling in these patients.  The IDENTIFY-HF study will investigate whether 
gradually increased arterial stiffness (in addition to ageing) as a result of increasing common 
comorbidities, such as hypertension and diabetes, is associated with HFpEF. 
Methods and analysis:
In our observational study arterial compliance and microvascular function will be assessed in five 
groups (Groups A to E) of age, sex and BMI matched subjects (age ≥ 70 years in all groups): 
Group A; normal healthy volunteers without major comorbidities such as hypertension and diabetes 
mellitus (control). Group B; patients with hypertension without diabetes mellitus or heart failure 
(HF). Group C; patients with hypertension and diabetes mellitus without HF.  Group D, patients with 
HFpEF; Group E; patients with heart failure and reduced ejection fraction (HFrEF) (parallel group). 
Vascular function and arterial compliance will be assessed using Pulse Wave Velocity, as the primary 
outcome measure. Further outcome measures include Cutaneous Laser Doppler Flowmetry as a 
measure of endothelial function, transthoracic echocardiography and exercise tolerance measures.  
Biomarkers include NT-proBNP, high sensitivity Troponin T, as well as serum galactin-3 as a marker 
of fibroses.
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Ethics and dissemination
The study was approved by the regional research ethics committee (REC), West Midland and Black 
Country 17/WM/0039, UK and permission to conduct the study in the hospital was also obtained 
from the RDI, UHCW NHS Trust.  The results will be published in peer-reviewed journals and 
presented in local, national and international medical society meetings.
  
Strengths and limitations of this study
• An important observational study aimed towards the understanding of the complex 
pathophysiology of HFpEF.
• Will provide insight whether the HFpEF syndrome is associated with increased arterial 
stiffness, as a result of increasing comorbidities.
• Comprehensive study of patients with increasing comorbidities investigating 
macrovascular/microvascular function, echocardiographic, biochemical and metabolomics to assess 
endothelial function in age, sex, and BMI-matched groups.
• The limitations of the study is that groups with more comorbidities (e.g. diabetes mellitus, 
hypertension and chronic kidney disease) should be included to fully investigate the potential effect 
of increasing comorbidities on arterial stiffness, which in turn, is associated with HFpEF.  Further, the 
cross-sectional design of the study with the related disadvantages
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INTRODUCTION
Heart failure (HF) is a major growing public health concern with approximately 20 million patients 
affected globally, posing a significant health economic burden, with an estimated cost of $108 billion 
per year worldwide.1 In the UK alone, approximately 5% of all emergency medical admissions are 
due to heart failure with an approximate cost to the National Health Service of £1.9 billion per year.2  
Heart failure with preserved ejection fraction (HFpEF) is reported to comprise about 50% of the total 
heart failure burden and continues to have a high and unchanged mortality over many years, a poor 
quality of life and similar readmission rates to HFrEF.3 4 The prognosis of HFpEF is comparable to 
systolic heart failure (SHF), now referred to as heart failure with reduced ejection fraction (HFrEF), 
with an estimated 5-year mortality of around 50%. This is worrying as no treatments that influence 
outcome in HFpEF have so far been found.5  Most large-scale pharmacological phase III clinical trials  
have been unsuccessful.6 7   Whilst there is no single reason contributing to the negative result of 
these trials, the most likely explanation is that our understanding of the pathophysiology of the 
HFpEF syndrome remains incomplete and we are, therefore, currently unable to produce therapies 
targeted at the underlying mechanisms causing the syndrome.8  Therefore, in order to develop 
evidence-based treatments in patients with HFpEF, the underlying diverse pathophysiology requires 
further investigation.  
Recently, there has been a shift in paradigm whereby comorbidities are thought to contribute 
significantly to HFpEF syndrome.9 Furthermore, current evidence strongly suggests that HFpEF 
patients have abnormal macro-and microvascular function with abnormal ventricular-vascular 
coupling.10  However, the effect of comorbidities on arterial stiffness and the HFpEF syndrome 
remains incompletely understood. 
This study aims to investigate the pathophysiological process of HFpEF and this understanding will 
promote further research, aiding the development of new evidence-based interventions and/or 
early prevention strategies.  
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Hypothesis 
HFpEF is a complex syndrome which is characterized by signs and symptoms of heart failure and a 
normal or a close to normal ejection fraction, evidence of left ventricular diastolic dysfunction, 
structural heart disease, altered left ventricular filling (LV) and raised brain natriuretic peptide 
(BNP)11. The complete pathophysiology is not known, however it is widely accepted that it is 
associated with cardiac and non-cardiac comorbidities12.  Cardiac abnormalities include altered atrial 
function, subtle alterations in LV systolic function and/or chronotropic incompetence.13  Non-cardiac 
comorbidities, for example hypertension, diabetes mellitus, anaemia, pulmonary or renal diseases 
and obesity may contribute to the HFpEF syndrome.  In terms of pathophysiology, diastolic 
dysfunction is a prominent feature of HFpEF patients to which many factors contribute including 
both myocardial and vascular stiffening14.  
HFpEF patients are known to have altered vascular function.  Balmain et al. investigated the 
comparison in arterial compliance, venous capacitance and microvascular vasodilator function in 3 
patients’ groups with HFpEF, HFrEF and normal volunteers (non-HF).  All the groups had coronary 
artery disease (CAD)15.  They found that there was reduced vascular compliance (increased arterial 
stiffness, decreased venous capacitance) in the HFpEF group compared to the HFrEF and non-HF 
groups. More recently, macro-and microvascular function was compared between HFpEF and 
hypertensive patients.16 This study found that there was decreased microvascular function with 
increase in arterial stiffness and depressed endothelial function in the forearm vasculature in the 
HFpEF group compared the hypertensive group. These studies highlight the fact that abnormal 
vasculature is present and may be an important contributor to the HFpEF syndrome. Although the 
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groups in the above-mentioned studies were matched for age and sex, what remains unclear is why 
certain patients of the same age and sex suffer from HFpEF whilst others do not. There is good 
evidence that hypertension17, diabetes mellitus18, and chronic kidney disease19 all increase vascular 
resistance on their own. Aging itself is known to be an independent risk factor for arterial stiffness 
and increase in pulse wave velocity.20 21 It is therefore reasonable to consider that HFpEF may not be 
due to a primary cardiac pathology but rather an end-result of non-cardiac comorbidities affecting 
vascular function and resistance with perhaps some secondary cardiac involvement.  We 
hypothesized therefore, that arterial stiffness increases with comorbidities, on top of effects of 
normal ageing (as illustrated in Figure 1), contributing towards the HFpEF syndrome. It is possible 
that a gradual increase in arterial stiffness may be causing early fatigue of the cardiac muscles (as it 
struggles to pump into an ever-increasing high-pressure vascular circuit) resulting in elevation of left 
ventricular end diastolic pressure and subsequently HFpEF22.
METHODS 
Study Design
Single-centre, observational study in 5 age, sex and BMI matched groups varying for the presence or 
absence of diabetes, hypertension or heart failure.
 Definitions
Heart failure in our study is defined as: a) relevant symptoms/signs/radiographic findings as 
indicated by Boston criteria 23 and b) need for diuretic therapy. Preserved LV systolic function is 
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defined as a LV ejection fraction (LVEF) of >50%, measured by echocardiography. Impaired LV 
systolic function will be defined as a LVEF of <40% in accordance with the European Society of 
Cardiology guidelines on heart failure.  LVEF will be calculated using semi- quantitative assessment 
with 16 segment wall motion scoring24. HFpEF, is defined as signs and symptoms of HF with 
LVEF>50% and raised natriuretic peptides (BNP>35pg/ml or NT-proBNP>125pg/ml) along with one 
other criteria: i) structural heart disease (left atrial enlargement or left ventricular hypertrophy) on 
TTE, ii) evidence of LV diastolic dysfunction based on ESC Guidelines 2016, or iii) hospitalization with 
heart failure within 12 months prior to study entry.
Hypertension is defined in this study as a documented resting clinic systolic blood pressure (SBP) 
>140 mmHg or Diastolic Blood Pressure (DBP) >90mmHg. Diabetes mellitus will be defined according 
to the World Health Organization (WHO) criteria.25  
Study Setting
The study will be conducted at two sites: the cardiology research department at University Hospitals 
Coventry & Warwickshire (UHCW) NHS Trust and at the cardiac rehabilitation facility of the hospital. 
The study assessments are expected to be undertaken during a single visit, however a second visit 
will be arranged if all the assessments are not completed. 
Study Population
Patients will be matched according to age, gender, Body Mass Index (BMI) and allocated to 5 
different groups. All patients will be aged 70 years or above. 
The first four groups will constitute: group A) normal healthy volunteers without major 
comorbidities including hypertension and diabetes, group B) patients with hypertension without 
diabetes mellitus, group C) patients with hypertension AND diabetes mellitus, and group D) patients 
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8
with HFpEF.  The fifth, parallel group E will comprise the HFrEF group.  In order to make meaningful 
comparison between the groups 21 patients each are planned to be recruited in groups A to D and 
11 in group E determined by sample size calculation.
Aims
We plan to assess vascular function, and cardiovascular performance in different cohorts (figure 2).   
Arterial resistance measured by pulse wave velocity (PWV) will be the primary outcome measure 
and will be compared between groups A to D. A separate comparison will be made between groups 
D and E. We intend to investigate if there is increased arterial resistance from group “A” to group 
“D” and if there is a significant difference in arterial resistance between groups “D” and “E. The 
secondary measures will focus on endothelial function (Laser Doppler measurements) and other 
cardiovascular performance measures; peak VO2 by Cardio-Pulmonary Exercise Test (CPEX), and 6-
minute walk distance. Bloods samples will be taken for NT-proBNP, high sensitivity Troponin T and 
serum will be stored for testing later for vascular biomarkers and galectin-3.
Inclusion Criteria 
● Group A: healthy males or females aged ≥ 70 years without major systemic illnesses including 
hypertension and diabetes mellitus.
● Group B: males or females aged ≥ 70 years with hypertension only.
● Group C: males or females aged ≥70 years with hypertension and diabetes mellitus but without 
HF. 
● Group D: males or females aged >70 years with HFpEF. 
● Group E: males or females aged ≥ 70 years with HFrEF.
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Exclusion criteria
 Acute coronary syndrome (including MI), cardiac surgery, other major CV surgery within 3 
months, or urgent percutaneous coronary intervention (PCI) within 30 days of entry.
 Patients who have had an MI, coronary artery bypass graft (CABG) or other event within the 
6 months prior to entry unless an echo measurement performed after the event confirms a 
LVEF ≥50%.
 Current acute decompensated HF requiring intravenous therapy
 Alternative reason for shortness of breath such as: significant pulmonary disease or severe 
COPD, haemoglobin (Hb) <10 g/dl, or body mass index (BMI) > 40 kg/m2.
 Severe left-sided valvular heart disease
 Hypotension (systolic BP <100 mm Hg).
 Severe Liver failure 
 Primary pulmonary hypertension
 Bedbound/immobile patients
 Chronic renal failure with creatinine of >250 μmol/l 
 Significant Peripheral Vascular Disease (PVD), defined as having signs of absent peripheral 
pulses or reported claudication pain or documented history of PVD 
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Sample size calculation and statistical analysis
The sample size calculation is based on estimates obtained in studies reported by Balmain et al26 and 
Marechaux et al.27  The aim is to detect a difference in the primary outcome; Pulse Wave Velocity 
(PWV), between the five groups of patients recruited to the study with the significance level being 
set at 5% if the p value is less than 0.05.  The estimates range from a mean PWV of 8.6 m/s for the 
control group to 11.3 m/s for the HFpEF group and the within group standard deviation is assumed 
to be SD=1.7 m/s and equal for each group.  No estimate of the mean PWV was available in the 
literature for the hypertension and Diabetes Mellitus group, so this value was assumed to be in 
exactly in the middle of the hypertension and HFpEF mean.  A sample size of n=11 for HFrEF patients 
and n=21 for all other groups will allow to detect a difference in PWV between the five groups for 
the aforementioned configuration of means and SD with 80% power using the overall F-test in a one-
way ANOVA.  The study would additionally be sufficiently powered for the pair-wise comparison of 
the control group with the hypertension group and the control group with the HFpEF group.  
Statistical analysis will be performed with IBM SPSS Statistics for Windows, version 22.0. Descriptive 
statistics will be given as number (percentage), as average (±SD) or median (interquartile range). 
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Study Procedures
Participants will attend our Research Unit in the morning.  To avoid confounding factors for vascular 
measurements, participants and will be asked to abstain from caffeine and tobacco for 12 hours, and 
to omit their morning blood pressure medication.  Vascular function studies will be carried out in a 
quiet, temperature-controlled (21–23 °C) room with subjects in the supine position, following at 
least 10 min of rest.  Arterial compliance will be assessed using applanation tonometry to measure 
aortic PWV. Cutaneous microvascular function will be assessed by Laser Doppler Flowmetry, after 
which the blood test and TTE measurements will be performed.  Subsequently, patients will be 
asked to undertake the 6-MWT and CPEX test (figure 2).
Screening and Recruitment 
Group A: Participants will be recruited via the UHCW Hospital Radio, senior citizen’s group in the 
community, and via friends and relatives of colleagues. These patients will receive an invitation 
letter and participant information sheet to read, they will then be contacted by the study 
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coordinator at least 24 hours after receiving the invitation letter to answer any questions. If the 
participant is interested in taking part in the study, they will be invited for a screening visit at UHCW 
to confirm their eligibility. This will involve a full medical history, physical examination, blood 
pressure measurement and blood tests (FBC, Glucose, HbA1c, and renal function). If the eligibility 
criteria are met, the study appointment will be organised.
Group B and C: Patients will be approached and screened for eligibility at the hypertension and 
diabetes outpatient clinics at UHCW. Eligible participants will receive an invitation letter and 
participant information sheet. They will then be contacted by the study coordinator at least 24 hours 
later to answer any questions, and to organise a study appointment .
Group D and E: Patients will be approached and screened for the eligibility criteria at the HF 
community clinic. Eligible participants will receive an invitation letter and participant information 
sheet. They will then be contacted by the study coordinator after at least 24 hours to answer any 
questions, and to organise a study appointment.
Study Assessments
Participants in all groups will have the same assessments as follows (table 1):
Blood pressure and heart rate measurement 
Heart rate and one brachial blood pressure measurement will be recorded over a 30s time period. 
These measurements will be performed 3 times for each subject and averaged. 
Blood tests will include full blood count, renal function and electrolytes, liver function tests, NT-
proBNP, and high-sensitive cardiac Troponin T (hs-cTnT). Blood samples will be frozen in the Tissue 
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bank at UHCW for further tests such as vascular and other biomarkers e.g. galectin-3 to be 
performed at a later date.
Urinalysis will be performed from a mid-stream urine sample obtained for albumin and creatinine 
levels.  This will further be stored at the Tissue Bank UHCW to be analysed at a later date for 
metabolite profiles (“metabolomics”), related to cardiovascular risk and insulin resistance. 
Transthoracic echocardiography (TTE) will include measurements of cardiac chamber sizes, 
ventricular function including LVEF, indices of LV diastolic function, assessment of valvular heart 
disease, tissue Doppler imaging and strain rate imaging. Furthermore, right ventricular structure and 
function and pulmonary artery pressures will be assessed.
Exercise tolerance will be assessed by a 6-minute walk test and a CPEX in each patient.  The CPEX 
test will involve measurement of the oxygen consumption and carbon dioxide production and heart 
rate and blood pressure monitoring whilst exercising on an exercise bike.  
Pulse wave velocity protocol 
Arterial resistance will be assessed using pulse wave velocity.  Aortic PWV will be evaluated using a 
high fidelity micromanometer (SPC-301; Millar Instruments, Texas, USA) coupled with the 
SphygmoCorTM system (SphygmoCor BPAS; PWV Medical, Sydney, Australia). A hand-held 
micromanometer-tipped probe will be applied to the skin overlying the radial, femoral and carotid 
arteries at the point of maximal arterial pulsation. Gated to a simultaneous electrocardiogram, the 
pulse wave will be recorded at each point.  This data, in combination with the measured body 
surface distance between the two points, will be incorporated by the software program to calculate 
Page 15 of 51
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
14
PWV in meters per second (m/s). The measurements will be repeated 3 times and the average PWV 
will be used for analysis.  
Laser Doppler Flowmetry (LDF) Protocol
The forearm cutaneous blood flow will be measured at rest and during reactive hyperaemia by using 
Laser Doppler Flowmetry (LDF), in accordance to the Fizeau-Doppler principle28.  Measurements of 
cutaneous blood flow will be expressed in perfusion units (PU) and the Laser Doppler signal will be 
continuously monitored on a computer (Moor instruments, VMS software V4.06) coupled with Moor 
instruments system (moorVMS-VASC).  The thenar eminence will be used for the placement of the 
LDF probe (VP1T/7), consistently at the same place, before and post the occlusive reactive 
hyperaemia manoeuvre.  The room temperature will be maintained at 22 degrees Celsius during 
forearm cutaneous blood flow measurements.  The reactive hyperaemia will be produced by 
occluding the forearm blood flow with a pneumatic cuff inflated to a pressure of 50 mm Hg above 
the Systolic Blood Pressure for 3 minutes. The signal obtained during complete arterial occlusion will 
be taken as the biologic zero for cutaneous blood flow measurements before and during reactive 
hyperaemia. Resting flow will be taken as the average of a 6-minute stable LDF recording. The 
definition of the measurements taken are shown in figure 3 and the power spectral density (PSD) 
will be measured using the basic fast Fourier transform algorithm29
Cardio-Pulmonary Exercise Test (CPEX)
Exercise tolerance will be assessed by 6-minute walk test and CPEX, conducted in accordance with 
existing guidelines30 31. For the walk test, participants will walk as far as possible in six minutes along 
a flat, obstacle free corridor, turning 180 degrees every 30m. For CPEX, participants will pedal a cycle 
ergometer at 70 rpm until volitional fatigue, using a ramp protocol. Breath-by-breath measurement 
of O2 consumption, CO2 production and ventilation will be used to determine key cardiorespiratory 
Page 16 of 51
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
15
parameters including peak O2 uptake (VO2 peak), VO2 at the anaerobic threshold (VO2 AT) and 
ventilatory efficiency (VE/VCO2). Blood pressure, ECG and O2 saturation will be continuously 
monitored. Criteria for a peak test will include respiratory exchange ratio (RER) >1.10 32.
Blinding
In order to reduce observer-bias the operator involved in the assessments of the primary outcome 
(pulse wave velocity) will be blinded to the comorbidities of the group of patients (A to E).  
Primary Outcome
Our primary outcome will be a difference in arterial resistance between each of the five groups, as 
measured by aortic PWV. In addition, specific comparisons will be made between the control and 
hypertension groups as well as the control and HFpEF groups.
Secondary Outcomes
The secondary outcomes are to assess and compare endothelial function and cardiovascular 
performance in all groups as measured by the following:
 Blood tests: NTproBNP, high sensitivity Troponin T, Galectin-3
 Urinalysis: Albumin, Creatinine and Metabolite profiles (“metabolomics”), related to 
cardiovascular risk and insulin resistance
 Transthoracic echocardiography (TTE) indices of LV diastolic function, tissue Doppler imaging, 
strain rate imaging and measuring flow with pulsed-wave Doppler echocardiography 
interrogating the LV outflow tract.
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 Exercise tolerance: 6-minute walk test and a Cardiopulmonary Exercise Test (CPEX) 
End of study definition
The study will be closed at the last patient’s study visit.
Study funding and sponsor
The study has been funded by a research grant from the West Midlands Clinical Research Network, 
National Institute of Health Research, UK. The study is sponsored by the Research, Development & 
Innovation department of the University Hospitals Coventry & Warwickshire NHS Trust (RDI, UHCW), 
UK.
Study oversight
The Study will be monitored and overseen by the Study Management Group and the Research, 
Development and Innovation Department at UHCW.
Ethical approval and research governance
The study was approved by the regional research ethics committee (REC), West Midland and Black 
Country 17/WM/0039, UK and permission to conduct the study in the hospital was also obtained 
from the RDI, UHCW NHS Trust.  The study will be conducted in compliance with the principles of the 
GCP guidelines and in accordance with all applicable regulatory guidance, including, but not limited 
to, the Research Governance Framework and the Health Research Authority, UK. Progress reports 
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and a final report at the conclusion of the study will be submitted to the approving REC within the 
timelines defined by the committee. 
Patient and public involvement
Patient involvement has been essential to the design of and protocol of the study.  Consultation has 
been obtained from patient and public involvement (PPI) representatives, which led to the tests 
being allowed to be done over two visits after screening.  The non-invasive nature of the 
investigations has been particularly likened by the PPI representative.  Furthermore, optional 
transport was provided to participants after their recommendation.   Patients seen in the relevant 
outpatient department will be invited to participate in the study.    On-going PPI input will occur 
during study steering committee.  The results of the study will be disseminated to all the participants 
via post. 
Dissemination and impact 
The hypothesis on which this study is based has been published.Error! Bookmark not defined. The 
results of the study will be presented at national and international conferences and released in 
appropriate media outlets, including social media. The results are expected to be published in peer-
reviewed journals and presented in local, national and international medical scientific congresses 
and meetings.  The study is anticipated to shed light on whether vascular stiffness is an important 
determinant of HFpEF which in turn could potentially encourage research for new therapeutic 
targets. 
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Contributor PB is the chief investigator for the study and DA leading on writing the protocol, ethics 
application and preparation of this manuscript.  FC, MW, MM all contributed fully to study design. 
GM, NC, SM, SE and RP contributed from their respective discipline and authored the relevant 
section of the protocol and manuscript.  All authors read and approved the final version of the 
manuscript.
Table 1: Schedule of measures for every participant within the study.
GROUP A ONLY: SEPARATE SCREENING VISIT PRIOR TO THE STUDY VISIT TO CHECK THAT THE 
PARTICIPANTS MEET THE ELIGIBILITY CRITERIA. FULL MEDICAL HISTORY, PHYSICAL EXAMINATION, 
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BLOOD PRESSURE AND BLOOD TESTS (FBC, GLUCOSE, HBA1C, AND RENAL FUNCTION).
TIME OF 
DAY
Procedures/Assessments*
Eligibility check
Informed consent
Demographic data (DOB, sex, ethnicity, height and weight) 
Relevant clinical history
Current medications
Blood pressure and Heart rate
Pulse Wave velocity (PWV) to measure arterial resistance
Laser Doppler to measure microvascular function
Blood tests: Full blood count, renal function and electrolytes, liver function tests, 
NT-proBNP, high-sensitive cardiac Troponin T (hs-cTnT). Samples will be frozen 
and stored for future analysis of vascular and other biomarkers e.g. Galectin-3
MORNING
Urine test: Albumin and Creatinine. Samples will be frozen and stored for future analysis 
of metabolite profiles
LUNCH
Transthoracic echocardiography (TTE): tissue Doppler imaging and strain rate 
imaging
6-minute walk test
AFTERNOON
Cardiopulmonary Exercise Test (CPEX)
All assessments will be aimed to be completed in a single visit.  However, a possible second visit can 
be arranged either at Atrium Health or University Hospitals Coventry and Warwickshire NHS Trust 
for completion of all assessments, if require.
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Figure 1: Overview of the hypothesis behind the IDENTIFY-HF study 
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Figure 2:Study Flow Chart 
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Figure 3 
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Abstract
Aims
There has been a paradigm shift proposing that comorbidities are a major contributor towards the 
heart failure with preserved ejection fraction (HFpEF) syndrome. Furthermore, HFpEF patients have 
abnormal macro and microvascular function, which may significantly contribute towards altered 
ventriculo-vascular coupling in these patients.  The IDENTIFY-HF study will investigate whether 
gradually increased arterial stiffness (in addition to ageing) as a result of increasing common 
comorbidities, such as hypertension and diabetes, is associated with HFpEF. 
Methods and analysis:
In our observational study arterial compliance and microvascular function will be assessed in five 
groups (Groups A to E) of age, sex and BMI matched subjects (age ≥ 70 years in all groups): 
Group A; normal healthy volunteers without major comorbidities such as hypertension and diabetes 
mellitus (control). Group B; patients with hypertension without diabetes mellitus or heart failure 
(HF). Group C; patients with hypertension and diabetes mellitus without HF.  Group D, patients with 
HFpEF; Group E; patients with heart failure and reduced ejection fraction (HFrEF) (parallel group). 
Vascular function and arterial compliance will be assessed using Pulse Wave Velocity, as the primary 
outcome measure. Further outcome measures include Cutaneous Laser Doppler Flowmetry as a 
measure of endothelial function, transthoracic echocardiography and exercise tolerance measures.  
Biomarkers include NT-proBNP, high sensitivity Troponin T, as well as serum galactin-3 as a marker 
of fibroses.
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Ethics and dissemination
The study was approved by the regional research ethics committee (REC), West Midland and Black 
Country 17/WM/0039, UK and permission to conduct the study in the hospital was also obtained 
from the RDI, UHCW NHS Trust.  The results will be published in peer-reviewed journals and 
presented in local, national and international medical society meetings.
  
Strengths and limitations of this study
• An important observational study aimed towards the understanding of the complex 
pathophysiology of HFpEF.
• Will provide insight whether the HFpEF syndrome is associated with increased arterial 
stiffness, as a result of increasing comorbidities.
• Comprehensive study of patients with increasing comorbidities investigating 
macrovascular/microvascular function, echocardiographic, biochemical and metabolomics to assess 
endothelial function in age, sex, and BMI-matched groups.
• The limitations of the study is that groups with more comorbidities (e.g. diabetes mellitus, 
hypertension and chronic kidney disease) should be included to fully investigate the potential effect 
of increasing comorbidities on arterial stiffness, which in turn, is associated with HFpEF.  Further, the 
cross-sectional design of the study with the related disadvantages
INTRODUCTION
Heart failure (HF) is a major growing public health concern with approximately 20 million patients 
affected globally, posing a significant health economic burden, with an estimated cost of $108 billion 
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per year worldwide.1 In the UK alone, approximately 5% of all emergency medical admissions are 
due to heart failure with an approximate cost to the National Health Service of £1.9 billion per year.2  
Heart failure with preserved ejection fraction (HFpEF) is reported to comprise about 50% of the total 
heart failure burden and continues to have a high and unchanged mortality over many years, a poor 
quality of life and similar readmission rates to HFrEF.3 4 The prognosis of HFpEF is comparable to 
systolic heart failure (SHF), now referred to as heart failure with reduced ejection fraction (HFrEF), 
with an estimated 5-year mortality of around 50%. This is worrying as no treatments that influence 
outcome in HFpEF have so far been found.5  Most large-scale pharmacological phase III clinical trials  
have been unsuccessful.6 7   Whilst there is no single reason contributing to the negative result of 
these trials, the most likely explanation is that our understanding of the pathophysiology of the 
HFpEF syndrome remains incomplete and we are, therefore, currently unable to produce therapies 
targeted at the underlying mechanisms causing the syndrome.8  Therefore, in order to develop 
evidence-based treatments in patients with HFpEF, the underlying diverse pathophysiology requires 
further investigation.  
Recently, there has been a shift in paradigm whereby comorbidities are thought to contribute 
significantly to HFpEF syndrome.9 Furthermore, current evidence strongly suggests that HFpEF 
patients have abnormal macro-and microvascular function with abnormal ventricular-vascular 
coupling.10  However, the effect of comorbidities on arterial stiffness and the HFpEF syndrome 
remains incompletely understood. 
This study aims to investigate the pathophysiological process of HFpEF and this understanding will 
promote further research, aiding the development of new evidence-based interventions and/or 
early prevention strategies.  
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Hypothesis 
HFpEF is a complex syndrome which is characterized by signs and symptoms of heart failure and a 
normal or a close to normal ejection fraction, evidence of left ventricular diastolic dysfunction, 
structural heart disease, altered left ventricular filling (LV) and raised brain natriuretic peptide 
(BNP)11. The complete pathophysiology is not known, however it is widely accepted that it is 
associated with cardiac and non-cardiac comorbidities12.  Cardiac abnormalities include altered atrial 
function, subtle alterations in LV systolic function and/or chronotropic incompetence.13  Non-cardiac 
comorbidities, for example hypertension, diabetes mellitus, anaemia, pulmonary or renal diseases 
and obesity may contribute to the HFpEF syndrome.  In terms of pathophysiology, diastolic 
dysfunction is a prominent feature of HFpEF patients to which many factors contribute including 
both myocardial and vascular stiffening14.  
HFpEF patients are known to have altered vascular function.  Balmain et al. investigated the 
comparison in arterial compliance, venous capacitance and microvascular vasodilator function in 3 
patients’ groups with HFpEF, HFrEF and normal volunteers (non-HF).  All the groups had coronary 
artery disease (CAD)15.  They found that there was reduced vascular compliance (increased arterial 
stiffness, decreased venous capacitance) in the HFpEF group compared to the HFrEF and non-HF 
groups. More recently, macro-and microvascular function was compared between HFpEF and 
hypertensive patients.16 This study found that there was decreased microvascular function with 
increase in arterial stiffness and depressed endothelial function in the forearm vasculature in the 
HFpEF group compared the hypertensive group. These studies highlight the fact that abnormal 
vasculature is present and may be an important contributor to the HFpEF syndrome. Although the 
groups in the above-mentioned studies were matched for age and sex, what remains unclear is why 
certain patients of the same age and sex suffer from HFpEF whilst others do not. There is good 
evidence that hypertension17, diabetes mellitus18, and chronic kidney disease19 all increase vascular 
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resistance on their own. Aging itself is known to be an independent risk factor for arterial stiffness 
and increase in pulse wave velocity.20 21 It is therefore reasonable to consider that HFpEF may not be 
due to a primary cardiac pathology but rather an end-result of non-cardiac comorbidities affecting 
vascular function and resistance with perhaps some secondary cardiac involvement.  We 
hypothesized therefore, that arterial stiffness increases with comorbidities, on top of effects of 
normal ageing (as illustrated in Figure 1), contributing towards the HFpEF syndrome. It is possible 
that a gradual increase in arterial stiffness may be causing early fatigue of the cardiac muscles (as it 
struggles to pump into an ever-increasing high-pressure vascular circuit) resulting in elevation of left 
ventricular end diastolic pressure and subsequently HFpEF22.
METHODS 
Study Design
Single-centre, observational study in 5 age, sex and BMI matched groups varying for the presence or 
absence of diabetes, hypertension or heart failure.
 Definitions
Heart failure in our study is defined as: a) relevant symptoms/signs/radiographic findings as 
indicated by Boston criteria 23 and b) need for diuretic therapy. Preserved LV systolic function is 
defined as a LV ejection fraction (LVEF) of >50%, measured by echocardiography. Impaired LV 
systolic function will be defined as a LVEF of <40% in accordance with the European Society of 
Cardiology guidelines on heart failure.  LVEF will be calculated using semi- quantitative assessment 
Page 34 of 51
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
7
with 16 segment wall motion scoring24. HFpEF, is defined as signs and symptoms of HF with 
LVEF>50% and raised natriuretic peptides (BNP>35pg/ml or NT-proBNP>125pg/ml) along with one 
other criteria: i) structural heart disease (left atrial enlargement or left ventricular hypertrophy) on 
TTE, ii) evidence of LV diastolic dysfunction based on ESC Guidelines 2016, or iii) hospitalization with 
heart failure within 12 months prior to study entry.
Hypertension is defined in this study as a documented resting clinic systolic blood pressure (SBP) 
>140 mmHg or Diastolic Blood Pressure (DBP) >90mmHg. Diabetes mellitus will be defined according 
to the World Health Organization (WHO) criteria.25  
Study Setting
The study will be conducted at two sites: the cardiology research department at University Hospitals 
Coventry & Warwickshire (UHCW) NHS Trust and at the cardiac rehabilitation facility of the hospital. 
The study assessments are expected to be undertaken during a single visit, however a second visit 
will be arranged if all the assessments are not completed. 
Study Population
Patients will be matched according to age, gender, Body Mass Index (BMI) and allocated to 5 
different groups. All patients will be aged 70 years or above. 
The first four groups will constitute: group A) normal healthy volunteers without major 
comorbidities including hypertension and diabetes, group B) patients with hypertension without 
diabetes mellitus, group C) patients with hypertension AND diabetes mellitus, and group D) patients 
with HFpEF.  The fifth, parallel group E will comprise the HFrEF group.  In order to make meaningful 
comparison between the groups 21 patients each are planned to be recruited in groups A to D and 
11 in group E determined by sample size calculation.
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Aims
We plan to assess vascular function, and cardiovascular performance in different cohorts (figure 2).   
Arterial resistance measured by pulse wave velocity (PWV) will be the primary outcome measure 
and will be compared between groups A to D. A separate comparison will be made between groups 
D and E. We intend to investigate if there is increased arterial resistance from group “A” to group 
“D” and if there is a significant difference in arterial resistance between groups “D” and “E. The 
secondary measures will focus on endothelial function (Laser Doppler measurements) and other 
cardiovascular performance measures; peak VO2 by Cardio-Pulmonary Exercise Test (CPEX), and 6-
minute walk distance. Bloods samples will be taken for NT-proBNP, high sensitivity Troponin T and 
serum will be stored for testing later for vascular biomarkers and galectin-3.
Inclusion Criteria 
● Group A: healthy males or females aged ≥ 70 years without major systemic illnesses including 
hypertension and diabetes mellitus.
● Group B: males or females aged ≥ 70 years with hypertension only.
● Group C: males or females aged ≥70 years with hypertension and diabetes mellitus but without 
HF. 
● Group D: males or females aged >70 years with HFpEF. 
● Group E: males or females aged ≥ 70 years with HFrEF.
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Exclusion criteria
 Acute coronary syndrome (including MI), cardiac surgery, other major CV surgery within 3 
months, or urgent percutaneous coronary intervention (PCI) within 30 days of entry.
 Patients who have had an MI, coronary artery bypass graft (CABG) or other event within the 
6 months prior to entry unless an echo measurement performed after the event confirms a 
LVEF ≥50%.
 Current acute decompensated HF requiring intravenous therapy
 Alternative reason for shortness of breath such as: significant pulmonary disease or severe 
COPD, haemoglobin (Hb) <10 g/dl, or body mass index (BMI) > 40 kg/m2.
 Severe left-sided valvular heart disease
 Hypotension (systolic BP <100 mm Hg).
 Severe Liver failure 
 Primary pulmonary hypertension
 Bedbound/immobile patients
 Chronic renal failure with creatinine of >250 μmol/l 
 Significant Peripheral Vascular Disease (PVD), defined as having signs of absent peripheral 
pulses or reported claudication pain or documented history of PVD 
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Sample size calculation and statistical analysis
The sample size calculation is based on estimates obtained in studies reported by Balmain et al26 and 
Marechaux et al.27  The aim is to detect a difference in the primary outcome; Pulse Wave Velocity 
(PWV), between the five groups of patients recruited to the study with the significance level being 
set at 5% if the p value is less than 0.05.  The estimates range from a mean PWV of 8.6 m/s for the 
control group to 11.3 m/s for the HFpEF group and the within group standard deviation is assumed 
to be SD=1.7 m/s and equal for each group.  No estimate of the mean PWV was available in the 
literature for the hypertension and Diabetes Mellitus group, so this value was assumed to be in 
exactly in the middle of the hypertension and HFpEF mean.  A sample size of n=11 for HFrEF patients 
and n=21 for all other groups will allow to detect a difference in PWV between the five groups for 
the aforementioned configuration of means and SD with 80% power using the overall F-test in a one-
way ANOVA.  The study would additionally be sufficiently powered for the pair-wise comparison of 
the control group with the hypertension group and the control group with the HFpEF group.  
Statistical analysis will be performed with IBM SPSS Statistics for Windows, version 22.0. Descriptive 
statistics will be given as number (percentage), as average (±SD) or median (interquartile range). 
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Study Procedures
Participants will attend our Research Unit in the morning.  To avoid confounding factors for vascular 
measurements, participants and will be asked to abstain from caffeine and tobacco for 12 hours, and 
to omit their morning blood pressure medication.  Vascular function studies will be carried out in a 
quiet, temperature-controlled (21–23 °C) room with subjects in the supine position, following at 
least 10 min of rest.  Arterial compliance will be assessed using applanation tonometry to measure 
aortic PWV. Cutaneous microvascular function will be assessed by Laser Doppler Flowmetry, after 
which the blood test and TTE measurements will be performed.  Subsequently, patients will be 
asked to undertake the 6-MWT and CPEX test (figure 2).
Screening and Recruitment 
Group A: Participants will be recruited via the UHCW Hospital Radio, senior citizen’s group in the 
community, and via friends and relatives of colleagues. These patients will receive an invitation 
letter and participant information sheet to read, they will then be contacted by the study 
coordinator at least 24 hours after receiving the invitation letter to answer any questions. If the 
participant is interested in taking part in the study, they will be invited for a screening visit at UHCW 
to confirm their eligibility. This will involve a full medical history, physical examination, blood 
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pressure measurement and blood tests (FBC, Glucose, HbA1c, and renal function). If the eligibility 
criteria are met, the study appointment will be organised.
Group B and C: Patients will be approached and screened for eligibility at the hypertension and 
diabetes outpatient clinics at UHCW. Eligible participants will receive an invitation letter and 
participant information sheet. They will then be contacted by the study coordinator at least 24 hours 
later to answer any questions, and to organise a study appointment .
Group D and E: Patients will be approached and screened for the eligibility criteria at the HF 
community clinic. Eligible participants will receive an invitation letter and participant information 
sheet. They will then be contacted by the study coordinator after at least 24 hours to answer any 
questions, and to organise a study appointment.
Study Assessments
Participants in all groups will have the same assessments as follows (table 1):
Blood pressure and heart rate measurement 
Heart rate and one brachial blood pressure measurement will be recorded over a 30s time period. 
These measurements will be performed 3 times for each subject and averaged. 
Blood tests will include full blood count, renal function and electrolytes, liver function tests, NT-
proBNP, and high-sensitive cardiac Troponin T (hs-cTnT). Blood samples will be frozen in the Tissue 
bank at UHCW for further tests such as vascular and other biomarkers e.g. galectin-3 to be 
performed at a later date.
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Urinalysis will be performed from a mid-stream urine sample obtained for albumin and creatinine 
levels.  This will further be stored at the Tissue Bank UHCW to be analysed at a later date for 
metabolite profiles (“metabolomics”), related to cardiovascular risk and insulin resistance. 
Transthoracic echocardiography (TTE) will include measurements of cardiac chamber sizes, 
ventricular function including LVEF, indices of LV diastolic function, assessment of valvular heart 
disease, tissue Doppler imaging and strain rate imaging. Furthermore, right ventricular structure and 
function and pulmonary artery pressures will be assessed.
Exercise tolerance will be assessed by a 6-minute walk test and a CPEX in each patient.  The CPEX 
test will involve measurement of the oxygen consumption and carbon dioxide production and heart 
rate and blood pressure monitoring whilst exercising on an exercise bike.  
Pulse wave velocity protocol 
Arterial resistance will be assessed using pulse wave velocity.  Aortic PWV will be evaluated using a 
high fidelity micromanometer (SPC-301; Millar Instruments, Texas, USA) coupled with the 
SphygmoCorTM system (SphygmoCor BPAS; PWV Medical, Sydney, Australia). A hand-held 
micromanometer-tipped probe will be applied to the skin overlying the radial, femoral and carotid 
arteries at the point of maximal arterial pulsation. Gated to a simultaneous electrocardiogram, the 
pulse wave will be recorded at each point.  This data, in combination with the measured body 
surface distance between the two points, will be incorporated by the software program to calculate 
PWV in meters per second (m/s). The measurements will be repeated 3 times and the average PWV 
will be used for analysis.  
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Laser Doppler Flowmetry (LDF) Protocol
The forearm cutaneous blood flow will be measured at rest and during reactive hyperaemia by using 
Laser Doppler Flowmetry (LDF), in accordance to the Fizeau-Doppler principle28.  Measurements of 
cutaneous blood flow will be expressed in perfusion units (PU) and the Laser Doppler signal will be 
continuously monitored on a computer (Moor instruments, VMS software V4.06) coupled with Moor 
instruments system (moorVMS-VASC).  The thenar eminence will be used for the placement of the 
LDF probe (VP1T/7), consistently at the same place, before and post the occlusive reactive 
hyperaemia manoeuvre.  The room temperature will be maintained at 22 degrees Celsius during 
forearm cutaneous blood flow measurements.  The reactive hyperaemia will be produced by 
occluding the forearm blood flow with a pneumatic cuff inflated to a pressure of 50 mm Hg above 
the Systolic Blood Pressure for 3 minutes. The signal obtained during complete arterial occlusion will 
be taken as the biologic zero for cutaneous blood flow measurements before and during reactive 
hyperaemia. Resting flow will be taken as the average of a 6-minute stable LDF recording. The 
definition of the measurements taken are shown in figure 3 and the power spectral density (PSD) 
will be measured using the basic fast Fourier transform algorithm29
Cardio-Pulmonary Exercise Test (CPEX)
Exercise tolerance will be assessed by 6-minute walk test and CPEX, conducted in accordance with 
existing guidelines30 31. For the walk test, participants will walk as far as possible in six minutes along 
a flat, obstacle free corridor, turning 180 degrees every 30m. For CPEX, participants will pedal a cycle 
ergometer at 70 rpm until volitional fatigue, using a ramp protocol. Breath-by-breath measurement 
of O2 consumption, CO2 production and ventilation will be used to determine key cardiorespiratory 
parameters including peak O2 uptake (VO2 peak), VO2 at the anaerobic threshold (VO2 AT) and 
ventilatory efficiency (VE/VCO2). Blood pressure, ECG and O2 saturation will be continuously 
monitored. Criteria for a peak test will include respiratory exchange ratio (RER) >1.10 32.
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Blinding
In order to reduce observer-bias the operator involved in the assessments of the primary outcome 
(pulse wave velocity) will be blinded to the comorbidities of the group of patients (A to E).  
Primary Outcome
Our primary outcome will be a difference in arterial resistance between each of the five groups, as 
measured by aortic PWV. In addition, specific comparisons will be made between the control and 
hypertension groups as well as the control and HFpEF groups.
Secondary Outcomes
The secondary outcomes are to assess and compare endothelial function and cardiovascular 
performance in all groups as measured by the following:
 Blood tests: NTproBNP, high sensitivity Troponin T, Galectin-3
 Urinalysis: Albumin, Creatinine and Metabolite profiles (“metabolomics”), related to 
cardiovascular risk and insulin resistance
 Transthoracic echocardiography (TTE) indices of LV diastolic function, tissue Doppler imaging, 
strain rate imaging and measuring flow with pulsed-wave Doppler echocardiography 
interrogating the LV outflow tract.
 Exercise tolerance: 6-minute walk test and a Cardiopulmonary Exercise Test (CPEX) 
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End of study definition
The study will be closed at the last patient’s study visit.
Study funding and sponsor
The study has been funded by a research grant from the West Midlands Clinical Research Network, 
National Institute of Health Research, UK. The study is sponsored by the Research, Development & 
Innovation department of the University Hospitals Coventry & Warwickshire NHS Trust (RDI, UHCW), 
UK.
Study oversight
The Study will be monitored and overseen by the Study Management Group and the Research, 
Development and Innovation Department at UHCW.
Ethical approval and research governance
The study was approved by the regional research ethics committee (REC), West Midland and Black 
Country 17/WM/0039, UK and permission to conduct the study in the hospital was also obtained 
from the RDI, UHCW NHS Trust.  The study will be conducted in compliance with the principles of the 
Page 44 of 51
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
17
GCP guidelines and in accordance with all applicable regulatory guidance, including, but not limited 
to, the Research Governance Framework and the Health Research Authority, UK. Progress reports 
and a final report at the conclusion of the study will be submitted to the approving REC within the 
timelines defined by the committee. 
Dissemination and impact 
The hypothesis on which this study is based has been published.Error! Bookmark not defined. The 
results of the study will be presented at national and international conferences and released in 
appropriate media outlets, including social media. The results are expected to be published in peer-
reviewed journals and presented in local, national and international medical scientific congresses 
and meetings.  The study is anticipated to shed light on whether vascular stiffness is an important 
determinant of HFpEF which in turn could potentially encourage research for new therapeutic 
targets. 
Patient and public involvement
Patient involvement has been essential to the design of and protocol of the study.  Consultation has 
been obtained from patient and public involvement (PPI) representatives, which led to the tests 
being allowed to be done over two visits after screening.  The non-invasive nature of the 
investigations has been particularly likened by the PPI representative.  Furthermore, optional 
transport was provided to participants after their recommendation.   Patients seen in the relevant 
outpatient department will be invited to participate in the study.    On-going PPI input will occur 
during study steering committee.  The results of the study will be disseminated to all the participants 
via post. 
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Table 1: Schedule of measures for every participant within the study.
GROUP A ONLY: SEPARATE SCREENING VISIT PRIOR TO THE STUDY VISIT TO CHECK THAT THE 
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PARTICIPANTS MEET THE ELIGIBILITY CRITERIA. FULL MEDICAL HISTORY, PHYSICAL EXAMINATION, 
BLOOD PRESSURE AND BLOOD TESTS (FBC, GLUCOSE, HBA1C, AND RENAL FUNCTION).
TIME OF 
DAY
Procedures/Assessments*
Eligibility check
Informed consent
Demographic data (DOB, sex, ethnicity, height and weight) 
Relevant clinical history
Current medications
Blood pressure and Heart rate
Pulse Wave velocity (PWV) to measure arterial resistance
Laser Doppler to measure microvascular function
Blood tests: Full blood count, renal function and electrolytes, liver function tests, 
NT-proBNP, high-sensitive cardiac Troponin T (hs-cTnT). Samples will be frozen 
and stored for future analysis of vascular and other biomarkers e.g. Galectin-3
MORNING
Urine test: Albumin and Creatinine. Samples will be frozen and stored for future analysis 
of metabolite profiles
LUNCH
Transthoracic echocardiography (TTE): tissue Doppler imaging and strain rate 
imaging
6-minute walk test
AFTERNOON
Cardiopulmonary Exercise Test (CPEX)
All assessments will be aimed to be completed in a single visit.  However, a possible second visit can 
be arranged either at Atrium Health or University Hospitals Coventry and Warwickshire NHS Trust 
for completion of all assessments, if require.
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